Nanomedicine in pulmonary delivery.

Heidi - Mansour, Yun Seok Rhee, Xiao Wu

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.

Original languageEnglish (US)
Pages (from-to)299-319
Number of pages21
JournalInternational Journal of Nanomedicine
Volume4
StatePublished - 2009
Externally publishedYes

Fingerprint

Nanomedicine
Medical nanotechnology
Drug delivery
Lung
Solubility
Pharmaceutical Preparations
Pulmonary diseases
Metabolism
Drug products
Aerosols
Toxicity
Availability
Inhalation Administration
Patient Compliance
Drug-Related Side Effects and Adverse Reactions
Incidence

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery

Cite this

Nanomedicine in pulmonary delivery. / Mansour, Heidi -; Rhee, Yun Seok; Wu, Xiao.

In: International Journal of Nanomedicine, Vol. 4, 2009, p. 299-319.

Research output: Contribution to journalArticle

Mansour, Heidi - ; Rhee, Yun Seok ; Wu, Xiao. / Nanomedicine in pulmonary delivery. In: International Journal of Nanomedicine. 2009 ; Vol. 4. pp. 299-319.
@article{6052377e26f6415bb275266d98d974a2,
title = "Nanomedicine in pulmonary delivery.",
abstract = "The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.",
author = "Mansour, {Heidi -} and Rhee, {Yun Seok} and Xiao Wu",
year = "2009",
language = "English (US)",
volume = "4",
pages = "299--319",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Nanomedicine in pulmonary delivery.

AU - Mansour, Heidi -

AU - Rhee, Yun Seok

AU - Wu, Xiao

PY - 2009

Y1 - 2009

N2 - The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.

AB - The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=77949501957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949501957&partnerID=8YFLogxK

M3 - Article

C2 - 20054434

AN - SCOPUS:77949501957

VL - 4

SP - 299

EP - 319

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -